Safety and Efficacy of Loco-regional B7H3 IL-7Ra CAR T Cell in DIPG

This trial is testing a new type of CAR-T cell therapy that targets two proteins (B7H3 and IL-7Ra) found on a deadly childhood brain tumor called diffuse intrinsic pontine glioma (DIPG). The engineered immune cells are delivered directly into the brain through a special reservoir device (like an Ommaya catheter). This is a safety and effectiveness trial for children who have already completed standard radiation therapy. **You may be eligible if...** - Your child has been diagnosed with DIPG at any time point after completing standard radiation therapy - Your child is aged 1–18 - Your child already has a brain reservoir catheter (such as Ommaya or Rickham) in place for treatment delivery - Your child's performance score is 60 or above (Lansky or Karnofsky) - Your child's expected survival is at least 8 weeks - Organ function (liver, kidneys, and oxygen levels) meets minimum thresholds **You may NOT be eligible if...** - Your child has a severe heart problem or significant cardiac arrhythmia - Your child has a primary immune deficiency or bone marrow failure syndrome - There is radiographic evidence of impending brain herniation - Your child has another active cancer (beyond DIPG) - Your child has grade 3 or higher difficulty swallowing Talk to your doctor to see if this trial is right for you.